860627P

C18 Dihydroceramide (d18:0/18:0)

Avanti Research^™ - A Croda Brand 860627P, powder

• 別名: N-stearoyl-D-erythro-sphinganine
• 実験式（ヒル表記法）: C₃₆H₇₃NO₃
• CAS番号: 2304-80-5
• 分子量: 567.97
• MDL番号: MFCD01076443
• UNSPSCコード: 12352211
• NACRES: NA.25

特性

• フォーム: powder
• 包装: pkg of 1 × 25 mg (860627P-25mg); pkg of 1 × 5 mg (860627P-5mg)
• メーカー／製品名: Avanti Research^™ - A Croda Brand 860627P
• 脂質タイプ: sphingolipids
• 輸送温度: dry ice
• 保管温度: −20°C
• SMILES記法: OC[C@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC
• InChI: 1S/C36H73NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h34-35,38-39H,3-33H2,1-2H3,(H,37,40)/t34-,35+/m0/s1
• InChI Key: KZTJQXAANJHSCE-OIDHKYIRSA-N

詳細

詳細

C18 Dihydroceramide (d18:0/18:0) or N-Stearoylsphinganine is a synthetic lipid. Acylation of sphinganine with stearoyl (FA-CoA with C18 acyl chain) by dihydro ceramide synthase 1,[1] yields C18-dihydroceramide.[2]

アプリケーション

C18 Dihydroceramide (d18:0/18:0) has been used as a standard for the quantitation of sphingolipid metabolites in adipose tissues by quadrupole time-of-flight (Q-TOF) mass spectrometry.[3]

生物化学的／生理学的作用

Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway.[4] vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients.[1] Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Therefore, it can be used as a predictor of graft rejection.[4]

包装

5 mL Amber Glass Screw Cap Vial (860627P-25mg)

5 mL Amber Glass Screw Cap Vial (860627P-5mg)

法的情報

Avanti Research is a trademark of Avanti Polar Lipids, LLC

安全性情報

• 保管分類コード: 11 - Combustible Solids